RAYMOND JAMES & ASSOCIATES - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 253 filers reported holding SAGE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$631,714
+55.0%
13,435
+38.3%
0.00%
Q1 2023$407,683
+69.5%
9,716
+54.1%
0.00%
Q4 2022$240,473
-66.9%
6,305
-35.0%
0.00%
-100.0%
Q1 2021$726,000
-34.2%
9,702
-24.0%
0.00%0.0%
Q4 2020$1,104,000
-81.3%
12,760
-86.8%
0.00%
-85.7%
Q3 2020$5,897,000
+418.6%
96,485
+252.9%
0.01%
+250.0%
Q2 2020$1,137,000
+89.2%
27,338
+30.5%
0.00%
+100.0%
Q1 2020$601,000
-3.4%
20,941
+143.2%
0.00%0.0%
Q4 2019$622,000
-87.4%
8,610
-75.6%
0.00%
-85.7%
Q3 2019$4,946,000
-27.8%
35,258
-5.7%
0.01%
-30.0%
Q2 2019$6,846,000
+30.0%
37,391
+12.9%
0.01%
+25.0%
Q1 2019$5,266,000
+144.2%
33,107
+47.1%
0.01%
+100.0%
Q4 2018$2,156,000
-30.2%
22,505
+2.9%
0.00%
-20.0%
Q3 2018$3,090,000
+6.5%
21,874
+18.0%
0.01%0.0%
Q2 2018$2,901,000
+26.6%
18,533
+30.2%
0.01%
+25.0%
Q1 2018$2,292,000
-4.6%
14,229
-2.4%
0.00%0.0%
Q4 2017$2,402,000
+172.0%
14,581
+2.9%
0.00%
+100.0%
Q3 2017$883,000
-51.4%
14,167
-37.9%
0.00%
-50.0%
Q2 2017$1,816,000
+79.4%
22,798
+60.1%
0.00%
+100.0%
Q1 2017$1,012,000
-19.0%
14,237
-41.8%
0.00%
-33.3%
Q4 2016$1,249,000
+266.3%
24,455
+230.3%
0.00%
+200.0%
Q3 2016$341,0007,4040.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q1 2018
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,966,688$120,204,00010.81%
Integral Health Asset Management, LLC 230,000$14,058,0004.30%
Asymmetry Capital Management, L.P. 102,462$6,262,0004.02%
ACUTA CAPITAL PARTNERS, LLC 225,000$13,752,0003.74%
DAFNA Capital Management LLC 158,306$9,676,0003.14%
Bain Capital Life Sciences Investors, LLC 499,100$30,505,0002.84%
Boxer Capital, LLC 1,094,000$66,865,0002.31%
Palo Alto Investors LP 590,200$36,073,0001.98%
Logos Global Management LP 250,000$15,280,0001.96%
Bellevue Group AG 1,579,504$96,539,0001.33%
View complete list of SAGE THERAPEUTICS INC shareholders